- 24/7 Wall St.•4 hours ago
Judging by this report, short sellers are making a tremendous bet against Trump’s plan to reform the health care sector.
- Reuters•5 hours ago
Israel-based Teva Pharmaceutical Industries said on Tuesday the U.S. Food and Drug Administration (FDA) has granted "priority review" for its SD-809 drug to treat tardive dyskinesia with a target date for approval by Aug. 30. A priority, or expedited, review allows for a faster evaluation of drug applications. Tardive dyskinesia, a condition for which there are no approved therapies in the United States, is a disorder characterised by repetitive and uncontrollable movements.
- Business Wire•5 hours ago
Teva Pharmaceutical Industries Ltd. today announced the U.S. Food and Drug Administration has accepted the New Drug Application and granted Priority Review for SD-809 for the treatment of tardive dyskinesia .
TEVA : Summary for Teva Pharmaceutical Industries - Yahoo Finance
Teva Pharmaceutical Industries Limited (TEVA)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||34.86 - 35.48|
|52 Week Range||31.90 - 59.35|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||499.43|
|Dividend & Yield||1.36 (3.84%)|
|1y Target Est||N/A|